Maintenance of efficacy and safety with subcutaneous golimumab in rheumatoid arthritis patients with low disease activity who previously received TNF inhibitors
Crossref DOI link: https://doi.org/10.1007/s10067-016-3502-8
Published Online: 2016-12-09
Published Print: 2017-04
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Wakabayashi, Hiroki
Inada, Hitoshi
Nishioka, Yosuke
Hasegawa, Masahiro
Sudo, Akihiro
Nishioka, Kusuki
License valid from 2016-12-09